\
&
Contact us
\
&
Contact us
This was 2 years ago
LocationHybrid event
The 2023 European Institute for Innovation through Health Data (i~HD) conference will provide participants with a broader scope for enabling trust in the secondary use of health data. i~HD will present its holistic view showing all important health data challenges to be solved in order to trustworthy use and reuse of high-quality data to continuously improve care and accelerate research.
Making a comeback in the i~HD conference is “Joining the Dots” where European funded projects tackling health data challenges will be brought together. Use cases, insights, successes and challenges will once again be front-and-centre as experts lead the sessions.
More information, the detailed programme and registration on the conference website.
Please be aware this is a paying event. Please make sure to check the ticket price before registry. You can opt for virtual participation or for on-site participation (including an optional social programme).
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
